Amersham Plc

Ge Healthcare Limited

Nycomed Amersham Plc

Susan Champion

Anthony Eamon Storey

Marivi Mendizabal

Peter Knox

Ian Andrew Wilson

Alex Gibson

Benedicte Guilbert

Alan Michael Forster

Timothy Charles Richardson

Richard Pither

Synthetic analogues of lysine and glutamine are provided which function as substrates for the fibrin-stabilising enzyme Factor XIIIa even when labelled with a detectable moiety. The use of suitable protecting groups provides compounds which possess reduced susceptibility to in vivo metabolism especially by peptidases, and are hence useful agents for the diagnosis of thrombosis, embolism, atherosclerosis, inflammation or cancer.

Labelled glutamine and lysine analogues

A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula (Y)-A-NHR)can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.

Labelled factor XIIIa substrates

Compounds of formula (I) where: X is OH or SH or NH or &mdash;L-Z; X and X are the same or different and each is H, C alkyl, benzyl a protecting group or &mdash;L-Z, X is H or C alkyl, L is a linker comprising a chain of 0-10 atoms, Z is a group comprising a detectable moiety which comprise at least one detectable moiety are useful in the diagnosis and prognosis and radiotherapy of metastatic bone disease.

Labelled ascorbic acid derivatives

A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula &mdash;(Y) &mdash;A&mdash;NHR, can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.

Growing community of inventors

Chesham, United Kingdom

Susan Champion